Lytix Biopharma held a Capital Markets Day primarily focusing on the core and versatility of the Lytix Technology Platform and selected parts of our clinical development program. The CMD was a live event (open for physical attendance at Hotel Continental in Oslo, Norway) and a live webcast.

The program included presentations and Q&A with 

• Øystein Rekdal, CEO of Lytix
  • What makes Lytix' immuno-oncology technology platform stand out as unique?
• Niels Junker, Chief Physician at Herlev Hospital and investigator at the ATLAS-IT-04 proof-of-concept study
  • Investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma – a pilot study.
• Aurélien Marabelle, Professor of Clinical Immunology, Université Paris Saclay and an internationally recognized expert on intratumoral cancer treatment
  • Liver cancer: Current treatment modalities and how oncolytic molecules could play an integral role in future liver cancer treatment.
• Stephen Worsley, CBO of Lytix
  • The commercial versatility of oncolytic molecules: What can LTX-315/401 bring to the immuno-oncology table/offer to the pharmaceutical industry.

The webcast replay is available here

For further information, please contact Ole Peter Nordby, Head of IR & Communication Manager (ole.peter.nordby@lytixbiopharma.com)